SubsidieMeestersPArtial REbreathing for Migraine with Aura
The Rehaler is a patented non-drug device for migraine with aura that aims to provide effective relief through CO2 and O2 modulation, supported by a large-scale clinical trial for regulatory approval.
Projectdetails
Introduction
Migraine with aura (MA) affects 4% of the global population, causing severe attacks that strongly impact patients’ quality of life. Currently available treatments are often ineffective, contraindicated, or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment. This indicates a large unmet clinical need and a significant commercial potential.
The Rehaler Medical Device
The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system.
Unique Commercial Advantages
The device has a unique commercial advantage by combining:
- A high treatment effect
- A low risk profile
- Simplicity, compactness, and affordability
Future Plans
To pave the way for regulatory approval, market launch, and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.481.076 |
| Totale projectbegroting | € 2.115.824 |
Tijdlijn
| Startdatum | 1-11-2023 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- REHALER ASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new life for people with severe disabling cluster headache: Neuromodulation therapy using safe, minimally-invasive simultaneous stimulation at the front and back of the head.Salvia BioElectronics is developing PRIMUS, a dual-site peripheral nerve modulator for drug-refractory chronic headaches, aiming for market launch by 2026 after successful clinical trials. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Miniaturised Respiratory Assist to treat acute lung failure patients using a breakthrough hyperbaric technologyHBOX Therapies aims to commercialize MiRA, a novel hyperoxygenation therapy for acute lung failure, enhancing patient outcomes while reducing reliance on invasive ventilation. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoringThe Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations. | EIC Accelerator | € 2.299.633 | 2023 | Details |
NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant EpilepsyNAO.VNS is an innovative implantable vagus nerve stimulator using optical fibers to enhance treatment for drug-resistant epilepsy, enabling personalized therapy and remote monitoring, with market approval expected by 2028. | EIC Accelerator | € 2.499.000 | 2023 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
A new life for people with severe disabling cluster headache: Neuromodulation therapy using safe, minimally-invasive simultaneous stimulation at the front and back of the head.
Salvia BioElectronics is developing PRIMUS, a dual-site peripheral nerve modulator for drug-refractory chronic headaches, aiming for market launch by 2026 after successful clinical trials.
Miniaturised Respiratory Assist to treat acute lung failure patients using a breakthrough hyperbaric technology
HBOX Therapies aims to commercialize MiRA, a novel hyperoxygenation therapy for acute lung failure, enhancing patient outcomes while reducing reliance on invasive ventilation.
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring
The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.
NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsy
NAO.VNS is an innovative implantable vagus nerve stimulator using optical fibers to enhance treatment for drug-resistant epilepsy, enabling personalized therapy and remote monitoring, with market approval expected by 2028.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Deelname aan de samenleving voor mensen met chronische migraine (LEEF)Het LEEF-project onderzoekt de haalbaarheid van een nieuwe neurostimulatie-therapie voor mensen met chronische migraine en clusterhoofdpijn. | Mkb-innovati... | € 20.000 | 2020 | Details |
Repurposed RoflumilastArega Medical herpositioneert Roflumilast voor vroege fase Alzheimer om het toegankelijk en betaalbaar te maken voor patiënten. | Mkb-innovati... | € 20.000 | 2022 | Details |
Saving the Brain of patient in emergencyHet project onderzoekt de haalbaarheid van een draagbaar koelingsapparaat om hersenletsel bij patiënten in noodsituaties te voorkomen. | Mkb-innovati... | € 20.000 | 2020 | Details |
PremoxHalcyon en Delft Solids Solutions ontwikkelen een draagbare koelgasgenerator voor medische zuurstof met >99% zuiverheid, die veilig, onderhoudsvrij en onafhankelijk van stroombronnen is. | Mkb-innovati... | € 344.779 | 2023 | Details |
Preclinical in vivo validation of a glioblastoma neuro snooper electrical deviceThis project aims to develop and validate the 'GBM Neuro Snooper' device to improve understanding and treatment of glioblastoma by assessing brain electrophysiology post-tumor resection. | ERC Proof of... | € 150.000 | 2023 | Details |
Deelname aan de samenleving voor mensen met chronische migraine (LEEF)
Het LEEF-project onderzoekt de haalbaarheid van een nieuwe neurostimulatie-therapie voor mensen met chronische migraine en clusterhoofdpijn.
Repurposed Roflumilast
Arega Medical herpositioneert Roflumilast voor vroege fase Alzheimer om het toegankelijk en betaalbaar te maken voor patiënten.
Saving the Brain of patient in emergency
Het project onderzoekt de haalbaarheid van een draagbaar koelingsapparaat om hersenletsel bij patiënten in noodsituaties te voorkomen.
Premox
Halcyon en Delft Solids Solutions ontwikkelen een draagbare koelgasgenerator voor medische zuurstof met >99% zuiverheid, die veilig, onderhoudsvrij en onafhankelijk van stroombronnen is.
Preclinical in vivo validation of a glioblastoma neuro snooper electrical device
This project aims to develop and validate the 'GBM Neuro Snooper' device to improve understanding and treatment of glioblastoma by assessing brain electrophysiology post-tumor resection.